Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280548742> ?p ?o ?g. }
- W4280548742 endingPage "197" @default.
- W4280548742 startingPage "188" @default.
- W4280548742 abstract "BackgroundIn the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated, unresectable/metastatic microsatellite instability−high (MSI-H)/mismatch repair‒deficient (dMMR) non-colorectal solid tumours. We present health-related quality of life (HRQoL) results from the MSI-H/dMMR population (cohort K).Patients and methodsEligible patients had previously treated MSI-H/dMMR advanced non-colorectal solid tumours, measurable disease per RECIST v1.1, and ECOG performance status ≤1. Patients received pembrolizumab 200 mg Q3W for 35 cycles (2 years). The EORTC Quality of Life Questionnaire (QLQ-C30) and EQ-5D-3L were administered at baseline, at regular intervals throughout treatment, and 30 days after treatment discontinuation. Prespecified analyses (exploratory endpoints) included the magnitude of change from baseline to post-baseline timepoints in all patients and by the best overall response for QLQ-C30 global health status (GHS)/QoL, QLQ-C30 functional/symptom scales/items, and EQ-5D-3L visual analogue scale (VAS) score.ResultsAt data cutoff (October 5, 2020), 351 patients were enrolled, of whom 311 and 315 completed baseline QLQ-C30 and EQ-5D-3L questionnaires, respectively. QLQ-C30 GHS/QoL scores improved from baseline to week 9 (mean [95% CI] change, 3.07 [0.19–5.94]), then remained stable or improved by week 111, with greater improvements observed in patients with a best response of complete response (CR) or partial response (PR) (10.85 [6.36–15.35]). Patients with CR/PR showed improvements in physical (5.58 [1.91–9.25]), role (9.88 [3.80–15.97]), emotional (5.62 [1.56–9.68]), and social (8.33 [2.70–13.97]) functioning, and stable cognitive functioning (1.74 [−1.45 to 4.94]).ConclusionsPembrolizumab generally improved or preserved HRQoL in patients with previously treated MSI-H/dMMR advanced non-colorectal solid tumours." @default.
- W4280548742 created "2022-05-22" @default.
- W4280548742 creator A5001115937 @default.
- W4280548742 creator A5008736570 @default.
- W4280548742 creator A5009198553 @default.
- W4280548742 creator A5018536695 @default.
- W4280548742 creator A5020672869 @default.
- W4280548742 creator A5027371764 @default.
- W4280548742 creator A5028121535 @default.
- W4280548742 creator A5029162966 @default.
- W4280548742 creator A5030448011 @default.
- W4280548742 creator A5039952118 @default.
- W4280548742 creator A5048013287 @default.
- W4280548742 creator A5053725787 @default.
- W4280548742 creator A5055850984 @default.
- W4280548742 creator A5059766169 @default.
- W4280548742 creator A5065206480 @default.
- W4280548742 creator A5080562953 @default.
- W4280548742 creator A5084542730 @default.
- W4280548742 creator A5085693851 @default.
- W4280548742 date "2022-07-01" @default.
- W4280548742 modified "2023-10-02" @default.
- W4280548742 title "Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study" @default.
- W4280548742 cites W1947168884 @default.
- W4280548742 cites W1970256118 @default.
- W4280548742 cites W1970908877 @default.
- W4280548742 cites W2123610405 @default.
- W4280548742 cites W2126623769 @default.
- W4280548742 cites W2165821117 @default.
- W4280548742 cites W2167571044 @default.
- W4280548742 cites W2287918349 @default.
- W4280548742 cites W2338340952 @default.
- W4280548742 cites W2733243250 @default.
- W4280548742 cites W2752236919 @default.
- W4280548742 cites W2763004155 @default.
- W4280548742 cites W2767287110 @default.
- W4280548742 cites W2906639914 @default.
- W4280548742 cites W2948941691 @default.
- W4280548742 cites W2980660242 @default.
- W4280548742 cites W2984359187 @default.
- W4280548742 cites W2990814876 @default.
- W4280548742 cites W3005292744 @default.
- W4280548742 cites W3091924577 @default.
- W4280548742 cites W3140137835 @default.
- W4280548742 cites W3170450105 @default.
- W4280548742 doi "https://doi.org/10.1016/j.ejca.2022.03.040" @default.
- W4280548742 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35588692" @default.
- W4280548742 hasPublicationYear "2022" @default.
- W4280548742 type Work @default.
- W4280548742 citedByCount "3" @default.
- W4280548742 countsByYear W42805487422022 @default.
- W4280548742 crossrefType "journal-article" @default.
- W4280548742 hasAuthorship W4280548742A5001115937 @default.
- W4280548742 hasAuthorship W4280548742A5008736570 @default.
- W4280548742 hasAuthorship W4280548742A5009198553 @default.
- W4280548742 hasAuthorship W4280548742A5018536695 @default.
- W4280548742 hasAuthorship W4280548742A5020672869 @default.
- W4280548742 hasAuthorship W4280548742A5027371764 @default.
- W4280548742 hasAuthorship W4280548742A5028121535 @default.
- W4280548742 hasAuthorship W4280548742A5029162966 @default.
- W4280548742 hasAuthorship W4280548742A5030448011 @default.
- W4280548742 hasAuthorship W4280548742A5039952118 @default.
- W4280548742 hasAuthorship W4280548742A5048013287 @default.
- W4280548742 hasAuthorship W4280548742A5053725787 @default.
- W4280548742 hasAuthorship W4280548742A5055850984 @default.
- W4280548742 hasAuthorship W4280548742A5059766169 @default.
- W4280548742 hasAuthorship W4280548742A5065206480 @default.
- W4280548742 hasAuthorship W4280548742A5080562953 @default.
- W4280548742 hasAuthorship W4280548742A5084542730 @default.
- W4280548742 hasAuthorship W4280548742A5085693851 @default.
- W4280548742 hasBestOaLocation W42805487421 @default.
- W4280548742 hasConcept C104317684 @default.
- W4280548742 hasConcept C121608353 @default.
- W4280548742 hasConcept C126322002 @default.
- W4280548742 hasConcept C141071460 @default.
- W4280548742 hasConcept C14184104 @default.
- W4280548742 hasConcept C143998085 @default.
- W4280548742 hasConcept C159110408 @default.
- W4280548742 hasConcept C180754005 @default.
- W4280548742 hasConcept C185592680 @default.
- W4280548742 hasConcept C2777701055 @default.
- W4280548742 hasConcept C2778715236 @default.
- W4280548742 hasConcept C2779767149 @default.
- W4280548742 hasConcept C2779951463 @default.
- W4280548742 hasConcept C2780057760 @default.
- W4280548742 hasConcept C2908647359 @default.
- W4280548742 hasConcept C526805850 @default.
- W4280548742 hasConcept C55493867 @default.
- W4280548742 hasConcept C61320498 @default.
- W4280548742 hasConcept C71924100 @default.
- W4280548742 hasConcept C72563966 @default.
- W4280548742 hasConcept C99454951 @default.
- W4280548742 hasConceptScore W4280548742C104317684 @default.
- W4280548742 hasConceptScore W4280548742C121608353 @default.
- W4280548742 hasConceptScore W4280548742C126322002 @default.
- W4280548742 hasConceptScore W4280548742C141071460 @default.
- W4280548742 hasConceptScore W4280548742C14184104 @default.
- W4280548742 hasConceptScore W4280548742C143998085 @default.